A review of opioid-based treatments for gambling disorder: an examination of treatment outcomes, cravings, and individual differences

References

• Aboujaoude, E., & Salame, W. O. (2016). Naltrexone: A pan-addiction treatment? CNS Drugs, 30, 719–733.10.1007/s40263-016-0373-0
   PubMed Web of Science ®Google Scholar
• Advokat, C. D., Comaty, J. E., & Julien, R. M. (2014). Julien’s primer of drug action: A comprehensive guide to the actions, uses, and side effects of psychoactive drugs (13th ed.). New York, NY: Worth Publishers.
   Google Scholar
• American Psychiatric Association. (1994). Diagnostics and Statistical Manual for Mental Disorders IV. Washington, DC: Author.
   Google Scholar
• American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders V. Washington, DC: Author.
   Google Scholar
• Apotex Inc. (2015). Product monograph: Apo-naltrexone. Naltrexone hydrochloride tablets usp. 50 mg. Opioid antagonist. Toronto, ON.: Apotex Inc.
   Google Scholar
• Aston-Jones, G., & Cohen, J. D. (2005). Adaptive gain and the role of the locus coeruleus-norepinephrine system in optimal performance. The Journal of Comparative Neurology, 493, 99–110.10.1002/(ISSN)1096-9861
   PubMed Web of Science ®Google Scholar
• Avants, S. K., Margolin, A., Kosten, T. R., & Cooney, N. L. (1995). Differences between responders and nonresponders to cocaine cues in the laboratory. Addictive Behaviors, 20, 215–224.10.1016/0306-4603(94)00066-2
   PubMed Web of Science ®Google Scholar
• Balodis, I. M., & Potenza, M. N. (2015). Anticipatory reward processing in addicted populations: A focus on the monetary incentive delay task. Biological Psychiatry, 77, 434–444.10.1016/j.biopsych.2014.08.020
   PubMed Web of Science ®Google Scholar
• Barr, C. S., Newman, T. K., Becker, M. L., Parker, C. C., Champoux, M., Lesch, K. P., … Higley, J. D. (2003). The utility of the non-human primate: Model for studying gene by environment interactions in behavioral research. Genes, Brain, and Behavior, 2, 336–340.10.1046/j.1601-1848.2003.00051.x
   PubMed Web of Science ®Google Scholar
• Bartley, C. A., & Bloch, M. H. (2013). Meta-analysis: Pharmacological treatment of pathological gambling. Expert Review of Neurotherapeutics, 13, 887–894.10.1586/14737175.2013.814938
   PubMed Web of Science ®Google Scholar
• Benjamin, D., Grant, E. R., & Pohorecky, L. A. (1993). Naltrexone reverses ethanol-induced dopamine release in the nucleus accumbens in awake, freely moving rats. Brain Research, 621, 137–140.10.1016/0006-8993(93)90309-B
   PubMed Web of Science ®Google Scholar
• Black, D. W., Monahan, P. O., Temkit, M., & Shaw, M. (2006). A family study of pathological gambling. Psychiatry Research, 141(3), 295–303.10.1016/j.psychres.2005.12.005
   PubMed Web of Science ®Google Scholar
• Blaszczynski, A., & Nower, L. (2002). A pathways model of problem and pathological gambling. Addiction, 97, 487–499.10.1046/j.1360-0443.2002.00015.x
   PubMed Web of Science ®Google Scholar
• Blum, K., Braverman, E. R., Holder, J. M., Lubar, J. F., Monastra, V. J., Miller, D., … Comings, D. E. (2000). Reward deficiency syndrome: A biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. Journal of Psychoactive Drugs, 32( suppl):1–112.10.1080/02791072.2000.10736099
   Web of Science ®Google Scholar
• Bobashev, G., Liao, D., Hampton, J., & Helzer, J. E. (2014). Individual patterns of alcohol use. Addictive Behaviors, 39, 934–940.10.1016/j.addbeh.2013.12.004
   PubMedGoogle Scholar
• Bosco, D., Plastino, M., Colica, C., Bosco, F., Arianna, S., Vecchio, A., … Consoli, D. (2012). Opioid antagonist naltrexone for the treatment of pathological gambling in Parkinson disease. Clinical Neuropharmacology, 35, 118–120.10.1097/WNF.0b013e31824d529b
   PubMed Web of Science ®Google Scholar
• Bouret, S., & Sara, S. J. (2005). Network reset: A simplified overarching theory of locus coeruleus noradrenaline function. Trends in Neurosciences, 28, 574–582.10.1016/j.tins.2005.09.002
   PubMed Web of Science ®Google Scholar
• Carter, B. L., & Tiffany, S. T. (1999). Meta-analysis of cue-reactivity in addiction research. Addiction, 94, 327–340.10.1046/j.1360-0443.1999.9433273.x
   PubMed Web of Science ®Google Scholar
• Castren, S., Salonen, A. H., Alho, H., Lathi, T., & Simojoki, K. (2015). Past-year gambling behaviour among patients receiving opioid substitution treatment. Substance Abuse Treatment, Prevention, and Policy, 10, 4.10.1186/1747-597X-10-4
   PubMed Web of Science ®Google Scholar
• Chamberlain, S. R., Muller, U., Blackwell, A. D., Clark, L., Robbins, T. R., & Sahakian, B. J. (2006). Neurochemical modulation of response inhibition and probabilistic learning in humans. Science, 311, 861–863.10.1126/science.1121218
   PubMed Web of Science ®Google Scholar
• Christensen, D. R., Jackson, A. C., Dowling, N. A., Volberg, R. A., & Thomas, S. A. (2015). An examination of a proposed DSM-IV pathological gambling hierarchy in a treatment seeking population: Similarities with substance dependence and evidence for three classification systems. Journal of Gambling Studies, 31, 787–806.10.1007/s10899-014-9449-2
   PubMed Web of Science ®Google Scholar
• Clark, L., Stokes, P. R., Wu, K., Michalczuk, R., Benecke, A., Watson, B. J., … Lingford-Hughes, A. R. (2012). Striatal dopamine D2/D3 rceptor binding in pathological gambling is correlated with mood-related impulsivity. NeuroImage, 63, 40–46.10.1016/j.neuroimage.2012.06.067
   PubMed Web of Science ®Google Scholar
• Cochran, B. N., Flentje, A., Heck, N. C., Van Den Bos, J., Perlman, D., Torres, J., … Carter, J. (2014). Factors predicting development of opioid use disorders among individuals who receive an initial opioid prescription: Mathematical modeling using a database of commercially-insured individuals. Drug Alcohol Dependence, 138, 202–208.10.1016/j.drugalcdep.2014.02.701
   PubMed Web of Science ®Google Scholar
• Comings, D. E., Gonzalez, N., Wu, S., Gade, R., Muhleman, D., Saucier, G., … MacMurray, J. P. (1999).  Studies of the 48 bp repeat polymorphism of the DRD4 gene in impulsive, compulsive, addictive behaviors: Tourette syndrome, ADHD, pathological gambling, and substance abuse. American Journal of Medical Genetics, 88, 358–368.10.1002/(ISSN)1096-8628
   PubMed Web of Science ®Google Scholar
• Crabbe, J. C. (2003). Finding genes for complex behaviors: Progress in mouse models of the addictions. In R. Plomin, J. DeFries, I. Craig, & P. McGuffin (Eds.), Behavioral genetics in the postgenomic era (pp. 291–308). Washington, DC: American Psychological Association.
   Google Scholar
• Crockford, D. N., & el-Guebaly, N. (1998). Naltrexone in the treatment of pathological gambling and alcohol dependence. The Canadian Journal of Psychiatry, 43, 86.
   PubMed Web of Science ®Google Scholar
• Crockford, D. N., Goodyear, B., Edwards, J., Quickfall, J., & el-Guebaly, N. (2005). Cue-induced brain activity in pathological gamblers. Biological Psychiatry, 58, 787–795.10.1016/j.biopsych.2005.04.037
   PubMed Web of Science ®Google Scholar
• Dannon, P. N., Lowengrub, K., Musin, E., Gonopolski, Y., & Kotler, M. (2005). Sustained-release bupropion vs. naltrexone in the treatment of pathological gambling. Journal of Clinical Psychopharmacology, 25, 593–596.10.1097/01.jcp.0000186867.90289.ed
   PubMed Web of Science ®Google Scholar
• de Castro, I. P., Ibanez, A., Saiz-Ruiz, J., & Fernandez-Piqeras, J. (2002). Concurrent positive association between pathological gambling and functional DNA polymorphisms at the MAO-A and the 5-HT transporter genes. Molecular Psychiatry, 7, 927–928.10.1038/sj.mp.4001148
   PubMed Web of Science ®Google Scholar
• de Ruiter, M. B., Veltman, D. J., Goudriaan, A. E., Oosterlaan, J., Sjoerds, Z., & van den Brink, W. (2009). Response preservation and ventral prefrontal sensitivity to reward and punishment in male problem gamblers and smokers. Neuropsychopharmacology, 34, 1027–1038.10.1038/npp.2008.175
   PubMed Web of Science ®Google Scholar
• Dick, D. M., Nurnberger, J., Jr, Edenberg, H. J., Goate, A., Crowe, R., Rice, J., … Foroud, T. (2002). Suggestive linkage on chromosome 1 for a quantitative alcohol-related phenotype. Alcoholism: Clinical and Experimental Research, 26, 1453–1460.10.1111/acer.2002.26.issue-10
   PubMed Web of Science ®Google Scholar
• Dick, D. M., Wang, J. C., Plunkett, J., Aliev, F., Hinrichs, A., Bertelsen, S., … Goate, A. (2007). Family-based association analyses of alcohol dependence phenotypes across DRD2 and neighbouring gene ANKK1. Alcoholism: Clinical and Experimental Research, 31, 1645–1653.10.1111/acer.2007.31.issue-10
   PubMed Web of Science ®Google Scholar
• Dowling, N. A., Jackson, A. C., Cowlishaw, S., Francis, K., Merkouris, S., & Christensen, D. R. (2015a). Prevalence of psychiatric comorbidity in treatment-seeking problem gambling: A systematic review and meta-analysis. Australian and New Zealand Journal of Psychiatry, 49, 6.
   Web of Science ®Google Scholar
• Dowling, N. A., Jackson, A. C., Cowlishaw, S., Francis, K., Merkouris, S., & Christensen, D. R. (2015b). The prevalence of comorbid personality disorders in treatment-seeking problem gamblers: A systematic review and meta-analysis. Journal of Personality Disorders, 29, 735–754.10.1521/pedi_2014_28_168
   PubMed Web of Science ®Google Scholar
• Ducci, F., & Goldman, D. (2012). The genetic bases of addictive disorders. Psychiatric Clinics of North America, 35, 495–519.10.1016/j.psc.2012.03.010
   PubMed Web of Science ®Google Scholar
• Dussault, F., Brendgen, M., Vitarom, F., Wanner, B., & Tremblay, R. E. (2011). Longitudinal links between impulsivity, gambling problems and depressive symptoms: A transactional model from adolescence to early adulthood. Journal of Child Psychology and Psychiatry, 52, 130–138.10.1111/j.1469-7610.2010.02313.x
   PubMed Web of Science ®Google Scholar
• Edenberg, H. J., Dick, D. M., Xuei, X., Tian, H., Almasy, L., Bauer, L. O., … Begleiter, H. (2004). Variations in GABRA2, encoding the alpha 2 subunit of the GABA(A) receptor, are associated with alcohol dependence and with brain oscillations. The American Journal of Human Genetics, 74, 705–714.10.1086/383283
   PubMed Web of Science ®Google Scholar
• el-Guebaly, N., Casey, D. M., Currie, S. R., Hodgins, D. C., Schopflocher, D. P., Smith, G. J., & Williams, R. J. (2015). The Leisure, Lifestyle, & Lifecycle Project (LLLP): A Longitudinal Study of Gambling in Alberta. Final Report for the Alberta Gambling Research Institute. February 2015.
   Google Scholar
• Ell, S. W., Marchant, N. L., & Irvy, R. B. (2006). Focal putamen lesions impair learning in rule-based, but not information-integration categorization tasks. Neuropsychologia, 44, 1737–1751.10.1016/j.neuropsychologia.2006.03.018
   PubMed Web of Science ®Google Scholar
• Francis, K. L., Dowling, N. A., Jackson, A. C., Christensen, D. R., & Wardle, H. (2015). Gambling motives: Application of the reasons for gambling questionnaire in an Australian population survey. Journal of Gambling Studies, 31, 807–823.10.1007/s10899-014-9458-1
   PubMed Web of Science ®Google Scholar
• Gahr, M., & Plener, P. L. (2016). Methylphenidate abuse: An overview. In V. R. Reedy (Ed.), Neuropathology of drug addictions and substance misuse: Volume 3: General processes and mechanisms, prescription medications, Caffeine and Areca, poly drug misuse, emerging addictions and non-drug addiction (pp. 651–659). London: Elsevier.
   Google Scholar
• Gaznick, N., Tranel, D., McNutt, A., & Bechara, A. (2014). Basal ganglia plus Insula damage yields stronger disruption of smoking addiction Than Basal Ganglia damage alone. Nicotine, 445–453.10.1093/ntr/ntt172
   PubMed Web of Science ®Google Scholar
• Giakoumaki, S. G., Roussos, P., & Bitsios, P. (2008). Improvement of prepulse inhibition and executive function by the COMT inhibitor tolcapone depends on COMT Val158Met polymorphism. Neuropsychopharmacology, 33, 3058–3068.10.1038/npp.2008.82
   PubMed Web of Science ®Google Scholar
• Goudriaan, A. E., de Ruiter, M. B., van den Brink, W., Oosterlaan, J., & Veltman, D. J. (2010). Brain activation patterns associated with cue reactivity and craving in abstinent problem gamblers, heavy smokers and healthy controls: An fMRI study. Addiction Biology, 15, 491–503.10.1111/adb.2010.15.issue-4
   PubMed Web of Science ®Google Scholar
• Goudriaan, A. E., Oosterlaan, J., de Beurs, E., & Van den Brink, W. (2004). Pathological gambling: A comprehensive review of biobehavioral findings. Neuroscience & Biobehavioral Reviews, 28, 123–141.10.1016/j.neubiorev.2004.03.001
   PubMed Web of Science ®Google Scholar
• Grant, J. E. (2016). Neurobiology of disordered gambling. Current Addiction Reports, 3, 445–449.10.1007/s40429-016-0119-6
   Google Scholar
• Grant, J. E., & Chamberlain, S. R. (2015). Psychopharmacological options for treating impulsivity. Psychiatric Times, 32, 58–65.
   Google Scholar
• Grant, J. E., Leppink, E. W., Redden, S. A., Odlaug, B. L., & Chamberlain, S. R. (2015). COMT genotype, gambling activity, and cognition. Journal of Psychiatric Research, 68, 371–376.10.1016/j.jpsychires.2015.04.029
   PubMed Web of Science ®Google Scholar
• Grant, J. E., Odlaug, B. L., & Chamberlain, S. R. (2016). Neural and psychological underpinnings of gambling disorder: A review. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 65, 188–193.
   PubMed Web of Science ®Google Scholar
• Grant, J. E., Odlaug, B. L., Potenza, M. N., Hollander, E., & Kim, S. W. (2010). Nalmefene in the treatment of pathological gambling: Multicentre, double-blind, placebo-controlled study. British Journal of Psychiatry, 197, 330–331.10.1192/bjp.bp.110.078105
   PubMed Web of Science ®Google Scholar
• Grant, J. E., Potenza, M. N., Hollander, E., Cunnigham-Williams, R., Nurminen, T., Smits, G., & Kallio, A. (2006). Multicenter Investigation of the Opioid Antagonist Nalmefene in the Treatment of Pathological Gambling. American Journal of Psychiatry, 163, 303–312.10.1176/appi.ajp.163.2.303
   PubMed Web of Science ®Google Scholar
• Grant, J. E., Kim, S.W., & Hartman, B. K. (2008). A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges. The Journal of Clinical Psychiatry, 69, 783–789.10.4088/JCP.v69n0511
   PubMed Web of Science ®Google Scholar
• Grant, J. E., Odlaug, B. L., & Schreiber, R. N. (2012). Pharmacological treatments in pathological gambling. British Journal of Clinical Pharmacology, 77, 375–381.
   Web of Science ®Google Scholar
• Hewig, J., Kretschmer, N., Trippe, R. H., Hecht, H., Coles, M. G. H., Holroyd, C. B., & Miltner, W. (2010). Hypersensitivity to reward in problem gamblers. Biological Psychiatry, 67, 781–783.10.1016/j.biopsych.2009.11.009
   PubMed Web of Science ®Google Scholar
• Hodgins, D. C., Stea, J. N., & Grant, J. E. (2011). Gambling disorders. Lancet, 378, 1874–1884.10.1016/S0140-6736(10)62185-X
   PubMed Web of Science ®Google Scholar
• Ibanez, A., de Castro, I. P., Fernandez-Piqueras, J., Blanco, C., & Saiz-Ruiz, J. (2000). Pathological gambling and DNA polymorphic markers at MAO-A and MAO-B genes. Molecular Psychiatry, 5, 105–109.10.1038/sj.mp.4000654
   PubMed Web of Science ®Google Scholar
• Jaffe, A. J., Rounsaville, G., Chang, G., Schottenfeld, R. S., Meyer, R. E., & O’Malley, S. S. (1996). Naltrexone, relapse prevention, and supportive therapy with alcoholics: An analysis of patient treatment matching. Journal of Consulting and Clinical Psychology, 64, 1044–1053.10.1037/0022-006X.64.5.1044
   PubMed Web of Science ®Google Scholar
• Johansson, A., Grant, J. E., Kim, S. W., Odlaug, B. L., & Gotestam, K. G. (2009). Risk factors for problematic gambling: A critical literature review. Journal of Gambling Studies, 25, 67–92.10.1007/s10899-008-9088-6
   PubMed Web of Science ®Google Scholar
• Kim, S. W., & Grant, J. E. (2001). An open naltrexone treatment study in pathological gambling disorder. International Clinical Psychopharmacology, 16, 285–289.10.1097/00004850-200109000-00006
   PubMed Web of Science ®Google Scholar
• Kim, S. W., Grant, J. E., Adson, D. E., & Shin, Y. C. (2001). Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biological Psychiatry, 49, 914–921.10.1016/S0006-3223(01)01079-4
   PubMed Web of Science ®Google Scholar
• Kovanen, L. Basnet, S., Castren, S., Pankakoski, M., Saarikoski, T., Alho, H., & Lahti, T. (2016). A randomised, double-blind, placebo-controlled trial of as-needed naltrexone in the treatment of pathological gambling. European Addiction Research, 22, 70–79.10.1159/000435876
   PubMed Web of Science ®Google Scholar
• Kranzler, H. R., Stephenson, J. J., Montejano, L., Wang, S., & Gastfriend, D. R. (2008). Persistence with oral naltrexone for alcohol treatment: Implications for health-care utilization. Addiction, 103, 1801–1808.10.1111/add.2008.103.issue-11
   PubMed Web of Science ®Google Scholar
• Lang, M., Lemenager, T., Streit, F., Fauth-Buhler, M., Frank, J., Juraeva, D., … Mann, K. F. (2016). Genome-wide association study of pathological gambling. European Psychiatry, 36, 38–46.10.1016/j.eurpsy.2016.04.001
   PubMed Web of Science ®Google Scholar
• Lathi, T., Halme, J. T., Pankakoski, M., Sinclair, D., & Alho, H. (2010). Treatment of pathological gambling with naltrexone pharmacotherapy and brief intervention: A pilot study. Psychopharmacology Bulletin, 43, 35–44.
   PubMedGoogle Scholar
• Ledgerwood, D. M., Knezevic, B., White, R., Khatib, D., Petry, N. M., & Diwadkar, V. A. (2014). Monetary delay discounting in a behavioral addiction sample: An fMRI pilot study. Drug and Alcohol Dependence, 140, e117–e118.10.1016/j.drugalcdep.2014.02.336
   Google Scholar
• Lind, P. A., Zhu, G., Montgomery, G. W., Madden, P. A. F., Heath, A. C., Martin, N. G., & Slutske, W. S. (2012). Genome-wide association study of quantitative disordered gambling trait. Addiction Biology, 18, 511–522.
   PubMed Web of Science ®Google Scholar
• Lindberg, A., Fernie, B. A., & Spada, M. M. (2011). Metacognitions in problem gambling. Journal of Gambling Studies, 27, 75–81.
   Web of Science ®Google Scholar
• Lobo, D. S., & Kennedy, J. L. (2009). Genetic aspects of pathological gambling: A complex disorder with shared genetic vulnerabilities. Addiction, 104(9), 1454–1465.10.1111/add.2009.104.issue-9
   PubMed Web of Science ®Google Scholar
• Lobo, D. S., Aleksandrova, L., Knight, J., Casey, D. N., el-Guebaly, N., & Kennedy, J. L. (2015). Addiction-related genes in gambling disorders: New insights from parallel human and pre-clinical models. Molecular Psychiatry, 20, 1002–1010.10.1038/mp.2014.113
   PubMed Web of Science ®Google Scholar
• Lorains, F. K., Cowlishaw, S., & Thomas, S. A. (2011). Prevalence of comorbid disorders in problem gambling ad pathological gambling: Systematic review and meta-analysis of population studies. Addiction, 106, 490–498.10.1111/add.2011.106.issue-3
   PubMed Web of Science ®Google Scholar
• Luczak, S. E., Glatt, S. J., & Wall, T. L. (2006). Meta-analyses of ALDH2 and ADH1B with alcohol dependence in Asians. Psychological Bulletin, 132, 607–621.10.1037/0033-2909.132.4.607
   PubMed Web of Science ®Google Scholar
• Luijten, M., Schellekens, A. F., Kuhn, S., Machielse, M. W. J., & Sescousse, G. (2017). Disruption o reward processing in addiction. An image-based meta-analysis of functional magnetic resonance imaging studies, 74, 387–398.
   Google Scholar
• MacKillop, J., Miller, J. D., Fortne, E., Maples, J., Lance, C. E., Campbell, W. K., & Goodie, A. S. (2014). Multidimensional examination of impulsivity in relation to disordered gambling. Experimental and Clinical Psychopharmacology, 22, 176–185.10.1037/a0035874
   PubMed Web of Science ®Google Scholar
• MacKillop, J., & Monti, P. M. (2007). Advances in the scientific study of craving for alcohol and tobacco: From scientific study to clinical practice. In P. M. Kavanagh (Ed.), Translation of Addictions Sciences in Practice (pp. 189–209). Amsterdam: Elsevier Press.
   Google Scholar
• Majuri, J., Joutsa, J., Johansson, J., Voon, V., Parkkola, R., Alho, H., … Kaasinen, V. (2017). Serotonin transporter density in binge eating disorder and pathological gambling: A PET study with [11C]MADAM. European Neuropsychopharmacology, 27, 1281–1288.10.1016/j.euroneuro.2017.09.007
   PubMed Web of Science ®Google Scholar
• Malhotra, A. K., Kestler, L. J., Mazzanti, C., Bates, J. A., Goldberg, T., & Goldberg, D. (2002). A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition. American Journal of Psychiatry, 159, 652–654.10.1176/appi.ajp.159.4.652
   PubMed Web of Science ®Google Scholar
• Meyer, M. C., Straughn, A. B., Lo, N. M. W., Schary, W. L., & Whitney, C. C. (1984). Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. The Journal of Clinical Psychiatry, 45, 15–19.
   PubMed Web of Science ®Google Scholar
• Miedl, S. F., Peters, J., & Buchel, C. (2012). Altered neural rewards representations in pathological gamblers revealed by delay and probability discounting. Archives of General Psychiatry, 69, 177–186.10.1001/archgenpsychiatry.2011.1552
   PubMed Web of Science ®Google Scholar
• Mueller, A., Armbruster, D., Moser, D. A., Canli, T., Lesch, K.-P., Brocke, B., & Kirschbaum, C. (2011). Interaction of serotonin transporter gene-linked polymorphic region and stressful life events predicts cortisol stress response. Neuropsychopharmacology, 36, 1332–1339.10.1038/npp.2011.11
   PubMed Web of Science ®Google Scholar
• Nordin, C., Gupta, R. C., & Sjodin, I. (2007). Cerebrospinal fluid amino acids in pathological gamblers and healthy controls. Neuropsychobiology, 56, 152–158.10.1159/000115782
   PubMed Web of Science ®Google Scholar
• Nutt, D. J. (2014). The role of the opioid system in alcohol dependence. Journal of Psychopharmacology, 28, 8–22.10.1177/0269881113504017
   PubMed Web of Science ®Google Scholar
• Pallanti, S., Bernardi, S., Allen, A., Chaplin, W., Watner, D., DeCaria, C. M., & Hollander, E. (2010). Noradrenergic function in pathological gambling: Blunted growth hormone response to clonidine. Journal of Psychopharmacology, 24, 847–853.10.1177/0269881108099419
   PubMed Web of Science ®Google Scholar
• Pallanti, S., DeCaria, C. M., Grant, J. E., Urpe, M., & Hollander, E. (2005). Reliability and validity of the pathological gambling adaptation of the Yale-Brown Obsessive-Compulsive Scale (PG-YBOCS). Journal of Gambling Studies, 21, 431–443.
   PubMed Web of Science ®Google Scholar
• Pallesen, S., Molde, H., Arnestad, H. M., Laberg, J. C., Skutle, A., Iversen, E., … Holsten, F. (2007). Outcome of pharmacological treatments of pathological gambling: A review and meta-analysis. Journal of Clinical Psychopharmacology, 27, 357–364.10.1097/jcp.013e3180dcc304d
   PubMed Web of Science ®Google Scholar
• Patrascu, M. C., Fainarea Alboaie, A. F., Androne, F. T., & Bratu-Bizic, R. E. (2017). Comparative efficacy analysis of naltrexone and selective serotonin reuptake inhibitors in pathological gambling treatment. European Neuropsychopharmacology, 27, S82–S83.10.1016/S0924-977X(17)30154-2
   PubMed Web of Science ®Google Scholar
• Pecina, S., Smith, K. S., & Berridge, K. C. (2006). Hedonic hot spots in the brain. The Neuroscientist, 12, 500–511.10.1177/1073858406293154
   PubMed Web of Science ®Google Scholar
• Petit, G., Luminet, O., Maurage, F., Tecco, J., Lechantre, S., Ferauge, M., … de Timary, P. (2015). Emotion regulation in alcohol dependence. Alcoholism: Clinical and Experimental Research, 39, 2471–2479.10.1111/acer.12914
   PubMed Web of Science ®Google Scholar
• Petrovic, P., Pleger, B., Seymour, B., Kloppel, S., De Martino, B., Critchley, H., & Dolan, R. J. (2008). Blocking central opiate function modulates hedonic impact and anterior cingulate response to rewards and losses. Journal of Neuroscience, 28, 10509–10516.10.1523/JNEUROSCI.2807-08.2008
   PubMed Web of Science ®Google Scholar
• Petry, N. M., & Roll, J. M. (2001). A behavioural approach to understanding and treating pathological gambling. Seminars in Clinical Neuropsychiatry, 6, 177–183.10.1053/scnp.2001.22920
   PubMedGoogle Scholar
• Pettorruso, M., Martinotti, G., Di Nicola, M., Onofrj, M., Di Giannantonio, M., Conte, G., & Janiri, L. (2012). Amantadine in the treatment of pathological gambling: A case report. Frontiers in Psychiatry, 3, article 102.
   PubMedGoogle Scholar
• Piz, L., Maremmani, A. G. I., Rovai, L., Bacciardi, S., Rugani, F., & Maremmani, I. (2013). Successful long-term (3-year) treatment of gambling with naltrexone. A case report. Heroin Addiction and Related Clinical Problems, 15, 47–54.
   Web of Science ®Google Scholar
• Potenza, M. N., Steinberg, M. A., Skudlarski, P., Fulbright, R. K., Lacadie, C. M., Wilber, M. K., … Wexler, B. E. (2003). Gambling urges in pathological gambling: A functional magnetic resonance imaging study. Archives of General Psychiatry, 60, 826–836.
   Google Scholar
• Potenza, M. N., Walderhaug, E., Henry, S., Gallezot, J.-D., Planeta-Wilson, B., Ropchan, J., & Neumeister, A. (2013). Serotonin 1B receptor imaging in pathological gambling. The World Journal of Biological Psychiatry, 14, 139–145.10.3109/15622975.2011.598559
   PubMed Web of Science ®Google Scholar
• Problem Gambling Research and Treatment Centre (2011). Guidelines for Screening, Assessment and Treatment in Problem Gambling. Clayton, Victoria: Melbourne and Monash Universities.
   Google Scholar
• Reuter, J., Taedler, T., Rose, M., Hand, I., Glascher, J., & Buchel, C. (2005). Pathological gambling is linked to reduce activation of the mesolimbic reward system. Nature Neuroscience, 8, 147–148.10.1038/nn1378
   PubMed Web of Science ®Google Scholar
• Robbins, T. W., & Everitt, B. J. (1996). Neurobehavioural mechanisms of reward and motivation. Current Opinion in Neurobiology, 6, 228–236.10.1016/S0959-4388(96)80077-8
   PubMed Web of Science ®Google Scholar
• Rose, R. J., Dick, D. M., Viken, R. J., Pulkkien, L., & Kaprio, J. (2001). Drinking or abstaining at age 14? A genetic epidemiological study. Alcoholism: Clinical and Experimental Research, 25, 1594–1604.10.1111/acer.2001.25.issue-11
   PubMed Web of Science ®Google Scholar
• Shippenberg, T. S. (2009). The dynorphin/kappa opioid receptor system: A new target for the treatment of addiction and affective disorders? Neuropsychopharmacology, 34, 247.10.1038/npp.2008.165
   PubMed Web of Science ®Google Scholar
• Slutske, W. S., Ellingson, J. M., Richmond-Rakerd, L. S., Zhu, G., & Martin, N. G. (2013). Shared genetic vulnerability for disordered gambling and alcohol use disorder in men and women: Evidence from a national community-based Australian twin study. Twin Research and Human Genetics, 16, 525–534.10.1017/thg.2013.11
   PubMed Web of Science ®Google Scholar
• Toneatto, T., Brands, B., Selby, P., & Sinclair, D. (2004). A randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of concurrent alcohol dependence and pathological gambling. Final Report submitted to the Ontario Problem Gambling Research Centre.
   Google Scholar
• Toneatto, T., Brands, B., & Selby, P. (2009). A randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of concurrent alcohol use disorder and pathological gambling. American Journal on Addictions, 18, 219–225.10.1080/10550490902787007
   PubMed Web of Science ®Google Scholar
• Tschernegg, M., Crone, J. S., Eigenberger, T., Schwartenbeck, P., Fauth-Buhler, M., Lemenager, T., … Kronbichler, M. (2013). Abnormalities of functional brain networks in pathological gambling: A graph-theoretical approach. Frontiers in Human Neuroscience, 7, 625.
   PubMed Web of Science ®Google Scholar
• van den Brink, W. (2012). Evidence-based pharmacological treatment of substance use disorders and pathological gambling. Current Drug Abuse Reviews, 5, 3–31.10.2174/1874473711205010003
   PubMedGoogle Scholar
• van Holst, R. J., van Holstein, M., van den Brink, W., Veltman, D. J., & Goudriann, A. E. (2012a). Response inhibition during cure reactivity in problem gamblers: an fMRI study. PLoS ONE, 7, e30909.10.1371/journal.pone.0030909
   PubMed Web of Science ®Google Scholar
• van Holst, R. J., Veltman, D. J., Buchel, C., van den Brink, W., & Goudriaan, A. E. (2012b). Distorted expectancy coding in problem gambling: Is the addictive in the anticipation? Biological Psychiatry, 71, 741–748.10.1016/j.biopsych.2011.12.030
   PubMed Web of Science ®Google Scholar
• Vasiliadis, S. D., Jackson, A. C., Christensen, D., & Francis, K. (2013). Physical accessibility of gambling opportunity and its relationship to gaming involvement and problem gambling: A systematic review. Journal of Gambling Issues, 18, 1–46.10.4309/jgi.2013.28.2
   Google Scholar
• Victorri-Vigneau, C., Spiers, A., Calliet, P., Bruneau, M., IGNACE-consortium, Challet-Bouju, G., & Grall-Bronnec, M. (2017). Opioid antagonists for pharmacological treatment of gambling disorder: Are the relevant? Current Neuropharmacology, 15, 1–15.
   Google Scholar
• Volkow, N. D., Fowler, J. S., & Wang, G. J. (2003). The addicted human brain: Insights from imaging studies. Journal of Clinical Investigation, 111, 1444–1451.10.1172/JCI18533
   PubMed Web of Science ®Google Scholar
• Williams, R. J., Hann, R., Schopflocher, D., West, B., McLaughlin, P., White, N., … Flexhaug, T. (2014). Quinte Longitudinal Study of Gambling and Problem Gambling. Report prepared for the Ontario Problem Gambling Research Centre.
   Google Scholar
• Windle, M., & Davies, P. (1999). Developmental theory and research. In K. E. Leonard & T. H. Blane (Eds.), Psychological Theories of Drinking and Alcoholism (pp. 164–202). New York, NY: Guilford Press.
   Google Scholar
• Xue, G., Lu, Z., Levin, I. P., & Bechara, A. (2010). The impact of prior risk experiences on subsequent risky decision-making: The role of the insula. NeuroImage, 50, 709–716.10.1016/j.neuroimage.2009.12.097
   PubMed Web of Science ®Google Scholar
• Yoon, G., & Kim, S. W. (2013). Monthly injectable naltrexone for pathological gambling. American Journal of Psychiatry, 170, 682–683.10.1176/appi.ajp.2013.12111469
   PubMed Web of Science ®Google Scholar